Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?

Tocilizumab is widely being used to treat COVID-19. Although reducing systemic inflammation, it also increases the risk for secondary infections as a result of the immunosuppression produced. We report the case of a 69-year-old patient admitted to the ICU with severe respiratory distress caused by C...

Descripción completa

Detalles Bibliográficos
Autores principales: Deana, Cristian, Vetrugno, Luigi, Bassi, Flavio, De Monte, Amato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
CAPA Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826035/
https://www.ncbi.nlm.nih.gov/pubmed/33520634
http://dx.doi.org/10.1016/j.mmcr.2021.01.002
_version_ 1783640446080122880
author Deana, Cristian
Vetrugno, Luigi
Bassi, Flavio
De Monte, Amato
author_facet Deana, Cristian
Vetrugno, Luigi
Bassi, Flavio
De Monte, Amato
author_sort Deana, Cristian
collection PubMed
description Tocilizumab is widely being used to treat COVID-19. Although reducing systemic inflammation, it also increases the risk for secondary infections as a result of the immunosuppression produced. We report the case of a 69-year-old patient admitted to the ICU with severe respiratory distress caused by COVID-19 pneumonia who developed pulmonary aspergillosis. On the basis of these findings, we suggest early testing for pulmonary aspergillosis in COVID-19 patients treated with tocilizumab.
format Online
Article
Text
id pubmed-7826035
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78260352021-01-25 Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline? Deana, Cristian Vetrugno, Luigi Bassi, Flavio De Monte, Amato Med Mycol Case Rep CAPA Case Report Tocilizumab is widely being used to treat COVID-19. Although reducing systemic inflammation, it also increases the risk for secondary infections as a result of the immunosuppression produced. We report the case of a 69-year-old patient admitted to the ICU with severe respiratory distress caused by COVID-19 pneumonia who developed pulmonary aspergillosis. On the basis of these findings, we suggest early testing for pulmonary aspergillosis in COVID-19 patients treated with tocilizumab. Elsevier 2021-01-21 /pmc/articles/PMC7826035/ /pubmed/33520634 http://dx.doi.org/10.1016/j.mmcr.2021.01.002 Text en © 2021 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle CAPA Case Report
Deana, Cristian
Vetrugno, Luigi
Bassi, Flavio
De Monte, Amato
Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
title Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
title_full Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
title_fullStr Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
title_full_unstemmed Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
title_short Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
title_sort tocilizumab administration in covid-19 patients: water on the fire or gasoline?
topic CAPA Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826035/
https://www.ncbi.nlm.nih.gov/pubmed/33520634
http://dx.doi.org/10.1016/j.mmcr.2021.01.002
work_keys_str_mv AT deanacristian tocilizumabadministrationincovid19patientswateronthefireorgasoline
AT vetrugnoluigi tocilizumabadministrationincovid19patientswateronthefireorgasoline
AT bassiflavio tocilizumabadministrationincovid19patientswateronthefireorgasoline
AT demonteamato tocilizumabadministrationincovid19patientswateronthefireorgasoline

Ejemplares similares